Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome

Overview

This study has three aims that hope to expand the knowledge on the cause of Sturge-Weber Syndrome (SWS) and improve clinical care of Sturge-Weber Syndrome patients.

Full Title of Study: “The Brain Vascular Malformations Clinical Research Network: Predictors of Clinical Course, Project 2: Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: July 2020

Detailed Description

This study is one of three projects of an NIH Rare Disease Clinical Research Consortium focused on brain blood vessel malformations in three different rare diseases. The focus of this project is on Sturge-Weber Syndrome. We plan to improve the future understanding and treatment of Sturge-Weber Syndrome by 1) establishing a national consortium database which will gather lager amounts of clinical data and serve indirectly as a registry to foster future clinical trials and determine the usefulness of urine vascular biomarkers to determine the vascular remodeling of the SWS birthmark and choroidal angioma, 2) study vascular remodeling with retrospective and prospective neuroimaging to determine the vascular remodeling of the deep draining intraparenchymal vessels as it relates to SWS neurologic status, and 3) relate the GNAQ mutation to altered phosphorylation of pathway proteins and angiogenesis factors in SWS tissue.

Clinical Trial Outcome Measures

Primary Measures

  • Aim 1
    • Time Frame: All 5 years
    • Descriptive statistics for the national database, correlation between neurologic score and urine angiogenesis factor, and correlation between PWS (port-wine stain) attributes, urine vascular factors, and neuroscore
  • Aim 2
    • Time Frame: All 5 years
    • Correlation between neuroscore and degree of collateral venous vessel opening
  • Aim 3
    • Time Frame: All 5 years
    • Correlation between GNAQ mutation status and hyperphosphorylation in downstream proteins

Participating in This Clinical Trial

Inclusion Criteria

For Aim 1: For main sample:

  • Sturge-Weber syndrome – Diagnosed brain Involvement For Control: – Family member of participating SWS patient For OCT: – Sturge-Weber syndrome eye involvement For Aim 2: – Sturge-Weber syndrome – Diagnosed Brain Involvement For Aim 3: – Sturge-Weber syndrome – Diagnosed brain Involvement – Port-Wine Stain in V1 and/or V2 areas of face. Exclusion Criteria:
  • Not Diagnosed with Sturge-Weber syndrome with brain Involvement (or eye involvement for OCT) For Aim 1: – Family member must not have certain medical conditions. A list will be provided before consent is given. For Aim 3: – Not Diagnosed with Sturge-Weber syndrome with brain Involvement – No Port-Wine Stain
  • Gender Eligibility: All

    Minimum Age: 1 Month

    Maximum Age: N/A

    Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

    Investigator Details

    • Lead Sponsor
      • Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
    • Collaborator
      • National Institutes of Health (NIH)
    • Provider of Information About this Clinical Study
      • Principal Investigator: Anne Comi, MD, Principal Investigator, Director Sturge-Weber Center, Kennedy Krieger Institute,Associate Professor Johns Hopkins University School of Medicine – Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
    • Overall Official(s)
      • Anne M Comi, M.D., Principal Investigator, Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.